Centiva Capital’s Summit Therapeutics SMMT Stock Holding History

Centiva Capital’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-29,225	Closed	-$228K	–	2567
2024 Q2	$228K	Buy	+29,225	New	+$158K	﹤0.01%	1610

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Centiva Capital's SMMT Position: Q3 2024 in Review

Centiva Capital sold out of Summit Therapeutics (SMMT) in Q3 2024, closing a stake of 29,225 shares — an estimated $228K sold.

Centiva Capital first reported a position in SMMT in Q2 2024 and held it in 1 quarter. The position peaked at $228K in Q2 2024. 166 funds tracked by Wall St. Rank hold SMMT as of Q3 2024.

Centiva Capital reported no remaining Summit Therapeutics position as of Q3 2024 after selling out during the quarter.
Centiva Capital sold 29,225 Summit Therapeutics shares in Q3 2024, an estimated $228K.
Centiva Capital first reported a position in Summit Therapeutics in Q2 2024 and held it in 1 quarter.
Centiva Capital's Summit Therapeutics position peaked at $228K in Q2 2024.
166 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.